|
|
Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment
The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alone. Biomarkers are increasingly incorporated into practice to aid in diagnosis of MCI and AD and to ... |
|
|
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease: Improving Diagnosis and Use of Targeted Therapies
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an eme... |
|
|
Maximizing Outcomes in Patients with Cognitive Impairments - Dr. Robert Winningham
Patients with cognitive impairment often have difficulty with functional activities as well as learning or relearning behaviors in the clinic. Many clients are functioning below their potential, because of fear or other psychological barriers. In addition, depressed, unmotivated, apathetic and/or anxious clients often do not benefit from treatment as much as others. As you know, these patients often pose difficult challenges for therapists. In this exciting and unique 2 day course, we will lea... |
|